Pharmaceutical Grade CAS 1197953-54-0 Ap26113 Powder Anti-Cancer Ap26113 Raw Materials Ap26113

• Customization: Available
• CAS No.: 1197953-54-0
• Formula: C29h39cln7o2p
• Model NO.: QS-Ap26113
• EINECS: 1592732-453-0
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: 2 Years
• Nutrient Composition: Ap26113
• Resource: Ap26113
• The content of active substances: 99%
• Product Name: Ap26113
• Name: Ap26113 Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Grade
• Specific: COA
• Test Method: HPLC
• CAS: 1197953-54-0
• Mf: C29h39cln7o2p
• MW: 584.09200
• Logp: 5.17680
• Density: 1.31
• Melting Point: 781.8
• Transport Package: Negotiabie
• Specification: 99%
• Trademark: QS
• Origin: Xi′an Shaanxi
• Production Capacity: 500kg/Month

Product Description

Pharmaceutical Grade CAS 1197953-54-0 Ap26113 Powder Anti-Cancer Ap26113 Raw Materials Ap26113

Product Description

Product Details

Product Name	Ap26113
Apperance	White Powder
CAS	1197953-54-0
MF	C29H39ClN7O2P
MW	584.09200

AP26113 (trade name: Brigatinib, brigatinib) is a highly efficient and selective small molecule tyrosine kinase inhibitor (TKI) with a CAS number of 1197953-54-0. Its chemical structure has been optimized and designed to target mutant proteins such as ALK (anaplastic lymphoma kinase) and ROS1, making it suitable for the treatment of non-small cell lung cancer (NSCLC). This drug has excellent blood-brain barrier penetration ability and can effectively inhibit tumor growth and metastasis. AP26113 is marketed in tablet form and has been clinically shown to have significant activity against drug-resistant mutations (such as ALK L1196M), making it an important representative of second-generation ALK inhibitors.

Application&Function

AP26113 selectively inhibits ALK and ROS1 kinase activity, blocks downstream signaling pathways such as STAT3, PI3K/AKT, and ERK, thereby inhibiting tumor cell proliferation and inducing apoptosis. It remains highly effective against multiple ALK resistant mutations (such as G1202R) and can penetrate the blood-brain barrier, effectively controlling central nervous system metastases. Clinical studies have shown that AP26113 can significantly prolong progression free survival (PFS) in ALK positive NSCLC patients and improve the prognosis of drug-resistant patients. Its dual inhibitory mechanism (ALK/EGFR) further broadens the therapeutic potential and becomes one of the key drugs for targeted therapy of advanced lung cancer.

Specification

ABOUT US